01 · THE CUSTOMER PROBLEM
Drug-delivery programs need to protect the active, control where it resides and manage how it is released without losing manufacturability or stability.
Mykito combines tunable cationic chemistry with particles, films, coatings and hydrogels to build route-specific delivery architectures.
Chitosan provides multiple ways to carry, protect and release an active ingredient across local and systemic delivery concepts.
02 · RECOMMENDED STARTING POINT
Start with the material designed for the decision.
Its cationic charge, reactive backbone and formability allow one engineered polymer to support nanoparticles, ocular systems, controlled-release matrices and targeted-delivery research.
Without the shell
Controlled fungal sourcing supports a traceable, non-animal supply strategy.
Specification engineered
MW, DDA, purity, charge density and format are selected around the target result.
Application ready
Powder is only the starting point; Mykito also develops films, fibers, gels, coatings and formulations.
One technical partner
Material selection, formulation support and the validation plan are connected from the first sample.
03 · PERFORMANCE TARGETS
Build toward outcomes a buyer can measure.
Controlled release
Matrix structure, crosslinking and degradation can be tuned to modify the rate and duration of release.
Nanoparticles
Ionic gelation and polymer complexation enable particulate carriers for small molecules, proteins and nucleic acids.
Ocular delivery
Mucoadhesive particles and gels can be developed to increase residence time on the ocular surface.
Targeted delivery
Functional groups allow conjugation and surface modification for tissue- or receptor-targeting research.
Adjuvant systems
Particulate and mucosal platforms can be investigated for co-delivery and adjuvant functions.
04 · GO / NO-GO CRITERIA
Define the evidence before testing begins.
The first program is designed around three decision-making outputs—not an open-ended material trial.
Loading and active protection
Residence and release kinetics
Stability, safety and route-specific performance
05 · FROM SAMPLE TO DECISION
A practical application program,
not a bag of powder.
Define
Agree on the function, baseline, constraints and measurable success criteria.
Screen
Select the MW, DDA, purity, dose and physical format that fit the application.
Validate
Test the winning system in the finished formulation, device, process or use environment.
Recommended first request: A route-specific EndoFree carrier-grade screening set and formulation brief.
Start the Sample Brief06 · WHY CHITOSAN
Cationic complexation + matrix control
Protonated amino groups can interact with selected anionic actives, polymers and biological surfaces. MW, DDA, crosslinking and architecture then provide levers for adhesion, protection and release.
There is no universal concentration. Grade and dose are screened against pH, interacting ingredients, process conditions and the target performance profile.
Route-specific purity, residuals, compatibility, stability and regulatory suitability are established for the finished system.